Effect of Different Wavelengths of Repeated Low-Level Light Therapy on Choroidal and Retinal Blood Flow Among Adults

NCT ID: NCT05796856

Last Updated: 2023-04-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-08
• Study Completion Date: 2023-07-15

Brief Summary

The purpose of this clinical trial is to evaluate the effect of different intensity of repeated low-level red-light (RLRL) therapy on the choroidal and retinal blood flow among adults.

Detailed Description

Repeated low-level red-light (RLRL) therapy is an emerging innovative and non-invasive treatment for a variety of eye diseases. Notably, RLRL was found to be effective in thickening choroidal thickness in a 1-year randomized controlled trial, indicating its potential in modulating blood flow in the fundus. However, it remains unclear how long it takes for the RLRL to make a difference in fundus blood flow and whether there is a dose-response.

The purpose of this study is to evaluate the different wavelengths of of repeated low level light therapy on the choroidal and retinal blood flow among adults. This study will be conducted with a randomized cross-over design with a total follow-up of 3 months. The repeated low level light therapy will be carried out in the study site under supervision according to a standard protocol. Detailed ophthalmic examinations, including visual acuity, intraocular pressure, optical coherence tomography/angiography, optical coherence tomography angiography, cycloplegic spherical equivalent refraction, slit lamp, and biological parameters will be evaluated at enrollment and during follow-ups.

Conditions

Choroid; Retina

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Repeated low-level light therapy (wavelength: 810 nm)

Participants will be treated with repeated low level light therapy (wavelength of 650 nm) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.

Single-vision spectacles with power for correcting distance refraction will also be used if necessary.

Group Type: EXPERIMENTAL

repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)

Intervention Type: DEVICE

crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.

Repeated low-level light therapy (wavelength: 650 nm)

Participants will be treated with repeated low level light therapy (wavelength of 650 nm) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.

Single-vision spectacles with power for correcting distance refraction will also be used if necessary.

Group Type: ACTIVE_COMPARATOR

repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)

Intervention Type: DEVICE

crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.

Interventions

repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)

crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age: 18-40 years at enrolment.

2. Healthy adults with best corrected visual acuity equal to or better than 1.0 in both eyes.

3. Provision of consent and able to participate in all required activities of the study.

Exclusion Criteria

1. Secondary myopia, such as a history of retinopathy of prematurity or neonatal problems, or syndromic myopia with a known genetic disease or connective tissue disorders, such as Stickler or Marfan syndrome; or high myopia < -8 diopters.

2. Strabismus and vision abnormalities (astigmatism > 3.5 D) in either eye.

3. Refractive media opacity: corneal opacities, cataracts, or implanted intraocular lens, etc.

4. Ocular abnormalities that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma, or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc.

5. Previous history of refractive surgery, intraocular surgery, laser therapy, and intravitreal injection, etc.

6. Systemic abnormalities: diabetes, hypertension, etc.

7. Drugs therapies with toxicity effects on the retina: hydroxychloroquine, etc.

8. Prior treatment of myopia control in the past three months including drugs, orthokeratology, progressive addition lenses, bifocal lenses, etc.

9. Other contraindications, including but not limited to ocular or other systemic abnormalities, that the physician may consider inappropriate for enrolment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

The Second People's Hospital of Foshan

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Xiangbin Kong, MD. PhD

Role: CONTACT

hxgcrco@shsyf.com

+862153555032

Shiran Zhang, MD

Role: CONTACT

shawn_zhangsr@hotmail.com

Other Identifiers

(2022)-0140

Identifier Type: -

Identifier Source: org_study_id